Abstract
Primary central nervous system lymphoma (PCNSL) is a relatively uncommon primary brain tumor, but it has become the focus of many clinical trials because of its rising incidence and unique sensitivity to systemic chemotherapeutic agents. Radiotherapy can achieve high response rates and remissions in most patients, but survival is usually only 12–18 months because disease recurs. The addition of systemic chemotherapy, particularly intravenous methotrexate, had markedly improved disease control and many patients can achieve a durable remission and occasionally cure of their disease. Conventional systemic lymphoma drug combinations such as cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) are ineffective. High-dose methotrexate is the single most active and important agent in the treatment of this disease. Whether improved disease control can be accomplished by adding other drugs to high-dose methotrexate or whether it is sufficient as a single agent has yet to be answered. High-dose methotrexate combined with cranial irradiation yields a median survival of at least 40 months and five year survival rates of 22%. However, neurotoxicity is substantial in a significant proportion of patients, particularly those over the age of 60 at the time of treatment. As many as 50% of such patients develop severe dementia. This is particularly important in a disease where approximately half of patients above the age of 60 had presentation. Efforts are now being directed towards not only improving disease control but also minimizing late neurotoxicity. Most efforts are currently directed towards using chemotherapy as the sole modality in the treatment of PCNSL, but both an optimal chemotherapy regimen, and the role of radiotherapy remain to be determined.
References
Eby NL, Grufferman S, Flannelly CM, Schold SC Jr, Vogel F, Burger PC: Increasing incidence of primary brain lymphoma in the US. Cancer 62: 2461–2465, 1988
DeAngelis LM: Current management of primary central nervous system lymphoma. Oncology 9: 63–78, 1995
DeAngelis LM, Yahalom J, Thaler HT, Kher U: Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10: 635–643, 1992
Reni M, Ferreri AJM, Garancini MP, Villa E: Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol 8: 227–234, 1997
Blay J-Y, Conroy T, Chevreau C, Thyss A, Quesnel, Eghbali, Bouabdallah R, Coiffier B, Wagner J-P, Le Mevel A, Dramais-Marcel D, Baumelou E, Chauvin F, Biron P: Highdose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 6: 864–871, 1998
Corry J, Smith JG, Wirth A, Quong, G, Liew KH: Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys 41: 615–620, 1998
Singh A, Strobos RJ, Singh BM, Rothballer AB, Reddy V, Puljic S, Poon TP: Steroid-induced remission in CNS lymphoma. Neurology 32: 1267–1271, 1982
Pirotte B, Levivier M, Goldman S, Brucher J-M, Brotchi J, Hildebrand J: Glucocorticoid-induced long-term remission in primary cerebral lymphoma: case report and reviewof the literature. J Neuro-Oncol 32: 63–69, 1997
DeAngelis LM, Yahalom J, Heinemann M-H, Cirrincione C, Thaler HT, Krol G: Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy. Neurology 40: 80–86, 1990
Bleyer WA: Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treat Rep 65 (Suppl 11): 89–98, 1981
Geyer JR, Taylor EM, Milstein JM: Radiation, methotrexate and white matter necrosis: laboratory evidence for neural radioprotection with preirradiation methotrexate. Int J Radiat Oncol Biol Phys 15: 373–375, 1988
Fisher RI, Gaynor ER, Dahlaberg S, OkenMM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New Eng J Med 328: 1002–1006, 1993
Lachance DH, Brizel DM, Gockerman JP, Halperin EC, Burger PC, Boyko OB, Brown MT, Schold SC: Cyclophosphamide, doxorubicin, vincristine and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy. Neurology 44: 1721–1727, 1994
Schultz C, Scott C, Sherman W, Donahue B, Fields J, Murray K, Fisher B, Abrams R, Meis-Kindblom J: Preirradiation chemotherapy with cyclophosphamide doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88–06. J Clin Oncol 14: 556–564, 1996
O'Neill BP, O'Fallon JR, Earle JD, Colgan JP, Brown LD, Krigel RL: Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy? Int J Rad Oncol Biol Phys 33: 663–673, 1995
Brada M, Dearnaley D, Horwich A, Bloom HJG: Management of primary cerebral lymphoma with initial chemotherapy: preliminary results and comparison with patients treated with radiotherapy alone. Int J Rad Oncol Biol Phys 18: 787–792, 1990
Ott RJ, Brada M, Flower MA, Babich JW, Cherry SR, Deehan BJ: Measurements of blood-brain barrier permeability inpatients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma. Eur J Cancer 27: 1356–1361, 1991
Ervin T, Canellos GP: Successful treatment of recurrent primary central nervous system lymphoma with high-dose methotrexate. Cancer 45: 1556–1557, 1980
Loeffler JS, Ervin TJ, Mauch P, Skarin A, Weinstein HJ, Canellos G, Cassady JR: Primary lymphomas of the central nervous system: patterns of failure and factors that influence survival. J Clin Oncol 3: 490–494, 1985
Gabbai AA, Hochberg FH, Linggood RM, Bashir R, Hotleman K: High-dose methotrexate for non-AIDS primary central nervous system lymphoma report of 13 cases. J Neurosurg 70: 190–194, 1989
21.Glass J, Gruber ML, Cher L, Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 81: 188–195
Abrey LE, DeAngelis LM, Yahalom J: Long-term survival in primary central nervous system lymphoma. J Clin Oncol 16: 1–6, 1998
DeAngelis LM, Delattre JY, Posner JB: Radiation-induced dementia in patients cured of brain metastases. Neurology 39: 789–796, 1989257
Merchut MP, Haberland C, Naheedy MH, Rubino FA: Long survival of primary cerebral lymphoma with progressive radiation necrosis. Neurology 35: 552–556, 1985
Chamberlain MC, Levin VA: Primary central nervous system lymphoma: a role for adjuvant chemotherapy. J Neuro-Oncol 14: 271–275, 1992
Cher L, Glass J, Harsh GR, Hochberg FH. Therapy of primary CNS lymphoma with methotrexatebased chemotherapy and deferred radiotherapy: preliminary results. Neurology 46: 1757–1759, 1996
Freilich RJ, Delattre J-Y, Monjour A, DeAngelis LM: Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 46: 435–439, 1996
Dahlborg SA, Henner WD, Crossen JR, Tableman M, Petrillo A, Braziel R, Neuwelt EA: Non-AIDS primary CNS lymphoma: first example of a durable response in a primary brain tumor using enhances chemotherapy delivery without cognitive loss and without radiotherapy. Cancer J Sci Am 2: 166–174, 1996
SandorV, Stark-VancsV, Pearson D, Nussenblat R, Whitcup SM, Brouwers P, Patronas N, Heiss J, Jaffe E, deSmet M, Kohler D, Simon R, Wittes R: Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 16: 3000–3006, 1998
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DeAngelis, L.M. Primary CNS Lymphoma: Treatment with Combined Chemotherapy and Radiotherapy. J Neurooncol 43, 249–257 (1999). https://doi.org/10.1023/A:1006258619757
Issue Date:
DOI: https://doi.org/10.1023/A:1006258619757